Viva Biotech Holdings · HKEX:1873
Viva Biotech — FY2024 Earnings Presentation
32 slides from Viva Biotech's earnings presentation, Mar 28, 2025
Slide 1: Viva Biotech 2024 Annual Results
Viva Biotech 2024 Annual Results 28 March 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain information set forth in this presentation contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our managemen
Slide 3: Contents
01 Business Highlights 02 Financial Performance CONTENTS 03 Future Strategies Q&A Session
Slide 4: Part 1: Business Highlights
Viva PART 1: Business Highlights
Slide 5: World Leading One-stop Innovative Original Drug R&D and Production Platform
World Leading One-stop Innovative Original Drug R&D and Production Platform CDMO Research and EFS Investment and CRO Business Production Business Incubation Business Focus on FIC's Discover business, take Provide innovative drug partners with small Focus on discovering and investing SBDD as the core
Slide 6: Equity Structure of Viva Biotech
Equity Structure of Viva Biotech Viva Biotech Holdings (1873.HK) 10.87% Strategic investors 26.34% 72.9% 100% 100% Small Molecule Incubator CRO CDMO 100% 100% 100% Incubators Onshore Equity Offshore Equity Shanghai Jiaxing Suzhou Chengdu Overseas Shanghai Ningbo Taizhou Holding Platform Holding Plat
Slide 7: Integrated Platform for Comprehensive Original Drug R&D and Manufacturing Services
Integrated Platform for Comprehensive Original Drug R&D and Manufacturing Services one-stop R&D service platform for innovative novel drugs Affinity-Based Drug Screening Mass Spectrometry (ASMS, INTACT-MS) SPR Drug Metabolism Crystal Soaking (ADME/DMPK) Protein Science and V-DEL Structural Research
Slide 8: Business Highlights Overview
Overview Business Highlights RMB Million Revenue in 2024FY reached RMB 1,986.7 million, -7.8% YOY Gross profit reached RMB 687.4 million, -6.9% YOY Gross profit margin 34.6%, +0.3pct YOY Adjusted net profit reached RMB 314.6 million, +50.6% YOY Adjusted Earnings per Share (EPS) of RMB 0.12
Slide 9: CRO Business: Revenue Growth Rate Improved Significantly in 2024H2
Overview CRO Business：Revenue Growth Rate Improved Significantly in 2024H2 and Is Expected to Continuously Pick Up in the Future Revenue: RMB 810.9 million, -4.0% YOY; however, the CFS SFE RMB Million CRO business revenue in 2024H2 has achieved YOY and 54.1 12.3 QOQ growth compared with the same p
Slide 10: CRO Business: Operational Efficiency and Number of Customers
CRO Business：Operational Efficiency Continues to Improve and the Number of Customers Grows Steadily CRO R&D Personnel Remain Stable and Served Top 50 Global Operational Efficiency Continues to Improve Pharmaceutical Companies 2024 1121 2023 1155 2022 1617 Based on Total Annual Revenue in 2024FY Numb
Slide 11: CRO Business: Targets and Protein Structures Delivered
CRO Business：Solid Operations with Continued Increase in the Number of Targets and Protein Structures Delivered Radiation Source Stage Unit: hours Number of Target and Protein Structure Deliveries 2024 1867 2023 2059 Independent Target Research: +112 YOY 2022 2064 Accumulative Research: 2098 M
Slide 12: AI Technology Driven Experiments Pave the Way for a New Era in Drug Development
AI Technology Driven Experiments Pave the Way for a New Era in Drug Development Target Safety and Efficacy Hit Identification Lead Optimization Identification Evaluation AI Structure Prediction Virtual Screening and Free Energy Perturbation ADME/PK Molecular Generation Property Prediction Viva Struc
Slide 13: AI-driven Drug Design – a New Pharmaceutical Logic
AI-driven Drug Design – a New Pharmaceutical Logic 16-25 weeks 6-12 weeks 6-24 months 12-36 months Screening Validation Hit-to-Lead Lead Optimization Target • Protein production • Resynthesis and testing • Compound activity optimization • Molecule design Selection • HTS screening • Orthogonal assay
Slide 14: CDMO R&D and Production Services Overview
Overview CDMO R&D and Production Services RMB Million Revenue of Langhua: RMB 1175.7 million, -10.3% YOY 261.0 Adjusted Gross Profit of Langhua: RMB 344.5 million, -11.4% YOY 253.6 CDMO: Revenue RMB 684.9 million, -6.7% YOY; adjusted gross profit margin 315.0 38.6%, remained flat YOY. 237.2
Slide 15: CDMO Business: Capacity Construction and New Commercial Project
CDMO Business: Capacity Construction Continuously Advance and a New Commercial Project Gets Ready to Launch Adjusted Gross Profit and Revenue from CDMO RMB Million 734.7 684.9 285.0 264.6 2023 2024 Revenue Adjusted gross profit margin Revenue from CDMO: RMB 684.9 million，decreased by 6.7% YOY; The
Slide 16: Langhua Factory's Capacity Building Status
Langhua Factory’s Capacity Building Status: Production Capacity Expansion Plan (2024-2026E) 2026E 1260 Cubic metres 2025 1260 (Expected to enter pilot production as early as 2025Q4) 2024 860 C 1 A1 B 1 Furthermore, Langhua Pharmaceutical plans to establish a new production capacity of 400 cubic me
Slide 17: CMC Business Optimized and Adjusted
CMC Business Has Been Basically Optimized and Adjusted, the Profitability will Improve in the Future Revenue Scale RMB CMC R&D Staff Persons ~ RMB56 million ~ RMB50 million 2024 105 ~RMB43 million 2023 113 2022 155 Historical Trends in the Cumulative Number of CMC Projects Projects 2022 2023 2024 20
Slide 18: EFS Investment & Incubation Business Overview
Overview EFS Investment & Incubation Business RMB Million As the end of the reporting period，the Group has invested a 1409.0 1241.2 1290.3 total of 93 portfolio companies. During the reporting period，several portfolio companies 1152.5 1180.4 achieved partially exits，which successfully realized t
Slide 19: VBI Investment Exits and Components Overview
VBI Investment Exits and Components Overview In 2024FY，VBI has invested in a total of 93 portfolio companies. In 2024FY，the Company achieved partial investment exits from several incubation portfolio companies, successfully realized investment income and received cash of approx. RMB 162.5 millio
Slide 20: Continuous Expansion of Drug Pipeline, with Ongoing Financing Progress
Continuous Expansion of Drug Pipeline, with Ongoing Financing Progress • Boehringer Ingelheim acquired Nerio Therapeutics in a deal valued 227 Pipeline Projects in Portfolio Companies up to US$1.3 billion for new immune checkpoint inhibitors. *Calculated Based on the Cumulative Number of Portfolio C
Slide 21: Key Projects in VBI Investment Portfolio
Key Projects in VBI Investment Portfolio No. Name Country Mechanism Indication Pipeline Company Overview Cardiovascular A precision medicine company focused on discovering and developing innovative tissue and cell-selective genomic drugs, its unique focus is RNA- Disease, guided programmable therape
Slide 22: Part 2: Financial Performance
PART 2: Financial Performance
Slide 23: Financial Performance of the Group
Financial Performance of the Group Revenue of the Group RMB million Adjusted Gross Profit RMB million 2155.6 1986.7 752.7 701.5 2023 2024 2023 2024 Adjusted Net Profit Experienced a Significant YOY Increase Adjusted EBITDA Experienced a YOY Increase RMB million RMB million Note:Investment Gain was n
Slide 24: CRO Financial Statistics
CRO Financial Statistics CRO Revenue RMB million Adjusted Gross Profit RMB million 845.0 810.9 363.8 357.1 2023 2024 2023 2024 No. of CRO R&D personnel Persons Annual revenue per CRO Personnel RMB’000 1155 1121 731.6 723.4 2023 2024 2023 2024 www.vivabiotech.com 24
Slide 25: CDMO Financial Statistics
CDMO Financial Statistics Revenue of Langhua Pharmaceutical RMB million Adjusted Gross Profit of Langhua Pharmaceutical RMB million 1310.7 1175.7 388.8 344.5 2023 2024 2023 2024 www.vivabiotech.com 25
Slide 26: Revenue Classifications of Principal Activities
Revenue Classifications of Principal Activities As at December 31, 2024 CDMO and commercialization Drug discovery services VBI Total service Types of goods or services RMB’000 RMB’000 RMB’000 RMB’000 Revenue from non-investees Full-time-equivalent (FTE) 595,470 - - 595,470 Fee-for-service (FFS) 157,
Slide 27: Items Measured at Fair Value with Changes in Fair Value Recognized in Profit or Loss
Items Measured at Fair Value with Changes in Fair Value Recognized in Profit or Loss The movements in the carrying value of unlisted investments at FVTPL for the reporting period are as follows ： RMB’000 January 1, 2023 1,046,616 Acquired 38,291 Recognized from SFE revenue 13,542 Loss on fair value
Slide 28: Appendix: Adjusted Non-IFRS Net Profit
APPENDIX: Adjusted Non-IFRS Net Profit 2024FY 2024H1 2023FY 2023H1 2022FY RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Net Profit / (Loss) 221,987 144,237 -99,790 13,659 -504,220 Add: Fair Value Gain on Financial Liabilities at -174,323 -10,050 FVTPL Add: interest expenses of the debt components of 124,3
Slide 29: Part 3: Future Strategies
Viva PART 3: Future Strategies
Slide 30: Improve Capacity Building for Front-end Projects, Expand Whole Industry Chain Service
Improve Capacity Building for Front-end Projects, Continue to Expand the Whole Industry Chain Service Downstream To Establish an Open and Cooperative Platform and a Win-win Ecosystem for Global Biopharmaceutical Innovators Early-stage preclinical service Raise technology barriers and expand servic
Slide 31: Q&A Session
Viva Q&A Session
Slide 32: Thanks
THANKS No.735, Ziping Road, Pudong New Area, Shanghai 201318, China —— Tel: +86 21 6089 3288 E-mail: info@vivabiotech.com www.vivabiotech.com